Protective Effect of Edaravone in Primary Cerebellar Granule Neurons against Iodoacetic Acid-Induced Cell Injury

Oxid Med Cell Longev. 2015:2015:606981. doi: 10.1155/2015/606981. Epub 2015 Oct 18.

Abstract

Edaravone (EDA) is clinically used for treatment of acute ischemic stroke in Japan and China due to its potent free radical-scavenging effect. However, it has yet to be determined whether EDA can attenuate iodoacetic acid- (IAA-) induced neuronal death in vitro. In the present study, we investigated the effect of EDA on damage of IAA-induced primary cerebellar granule neurons (CGNs) and its possible underlying mechanisms. We found that EDA attenuated IAA-induced cell injury in CGNs. Moreover, EDA significantly reduced intracellular reactive oxidative stress production, loss of mitochondrial membrane potential, and caspase 3 activity induced by IAA. Taken together, EDA protected CGNs against IAA-induced neuronal damage, which may be attributed to its antiapoptotic and antioxidative activities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipyrine / analogs & derivatives*
  • Antipyrine / pharmacology
  • Apoptosis / drug effects
  • Caspase 3 / metabolism
  • Cell Survival / drug effects
  • Cells, Cultured
  • Edaravone
  • Iodoacetic Acid / toxicity*
  • Membrane Potential, Mitochondrial / drug effects
  • Microscopy, Fluorescence
  • Neurons / cytology
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Neuroprotective Agents
  • Caspase 3
  • Edaravone
  • Antipyrine
  • Iodoacetic Acid